Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
Crossref DOI link: https://doi.org/10.1007/s00280-017-3452-0
Published Online: 2017-11-08
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schmid, Ulrike
Liesenfeld, Karl-Heinz
Fleury, Angele
Dallinger, Claudia
Freiwald, Matthias
License valid from 2017-11-08